按治疗类型、药物类别、最终用户、通路、给药途径、患者年龄层和PFIC类型分類的进行性遗传性肝内胆汁淤积症治疗市场 - 全球预测 2025-2032

预计到 2032 年，进行性遗传性肝内胆汁淤积症治疗市场将成长至 1.7,281 亿美元，复合年增长率为 4.81%。

关键市场统计数据
基准年 2024	1.1862亿美元
预计年份：2025年	1.244亿美元
预测年份 2032	1.7281亿美元
复合年增长率 (%)	4.81%

本书对进行性家族性肝内胆汁淤积症（PFIC）的临床、治疗和运作方面进行了简明扼要、权威的概述，并阐明了各相关人员的战略重点。

进行性遗传性肝内胆汁淤积症 (PFIC) 是一种遗传和临床表现异质性很强的胆汁淤积性肝病，在诊断、临床管理和长期照护方面都面临着许多挑战。患者自幼年起便出现进行进行性肝功能障碍，通常需要药物、支持性治疗、手术等多种方法的综合治疗。因此，临床医生、研究人员和医疗保健系统都在寻求多管齐下的策略，力求在短期控制症状的同时，透过持续干预来改变疾病的生物机制。

本执行摘要组装了目前进行性家族性肝内胆汁淤积症 (PFIC) 治疗的格局，综合分析了各种治疗方法、监管路径和治疗模式的最新进展。摘要重点阐述了重塑临床优先事项的驱动因素，包括旨在降低肝内胆汁酸负荷的新型标靶药物、不断发展的肝移植和肝再形成手术标准，以及专科医疗网络的日益成熟。此外，摘要还强调了将临床创新与供应链韧性、支付方参与和以患者为中心的医疗模式相结合的重要性，以确保先进疗法能够带来公平的实际益处。在此背景下，引言部分为读者深入探讨变革性转变、细分资讯、区域洞察以及针对整个治疗生态系统相关人员的战术性建议做好了准备。

新的治疗创新、适应性监管方法和整合式照护模式正在融合，重新定义进行性家族性肝内胆汁淤积症（PFIC）的治疗范式和应用路径。

近年来，科学、监管和医疗服务等多面向因素的共同作用，为进行性家族性肝内胆汁淤积症（PFIC）的治疗格局带来了变革性变化。分子遗传学的进步和对胆汁酸生理学更深入的理解，加速了标靶药物疗法的研发，这些疗法能够直接调节肠肝胆汁酸循环。这项发展使得治疗选择不再局限于针对症状的支持性治疗，而是扩展到能够改变疾病进程、延缓甚至避免侵入性手术介入的药物。

同时，临床实践正开始采用更一体化的医疗模式，将肝病专科中心、协调的营养支持以及早期转诊途径纳入移植评估。监管机构正在提供适应性路径和孤儿药奖励，以加速罕见疾病治疗方法的研发。诊断技术的进步、标靶药物研发管线的不断扩充以及健保报销机制的演变，共同推动着策略重点的转变。申办方现在必须制定差异化的临床方案、为支付者提供清晰的实证策略，并与专科诊所和移植中心伙伴关係，以支持病患监测。

评估美国计划于 2025 年征收的关税将如何影响 PFIC 疗法的供应链、临床项目、采购和患者获取途径。

美国近期宣布的将于2025年生效的关税，透过影响跨境供应链的经济和物流，为被动外国干预性免疫缺陷（PFIC）治疗生态系统增添了新的复杂性。许多专科药物、原料和生物製药都依赖国际生产和分销网络。如果关税导致活性原料药、最终产品和辅助器具的境内价格上涨，申办方和经销商将面临压力，必须重新评估其筹资策略、库存管理以及与生产合作伙伴的合约条款。

这些成本压力也将波及医院、专科诊所和药局管道的采购惯例，迫使它们加强与生产商的谈判，并更严格地评估处方发放情况。临床开发项目也将受到影响。临床实验药物的供应预算、进出口计划以及临床实验试验地点的选择可能需要进行调整，以确保临床实验药物供应的连续性。为此，相关人员正在优先考虑供应链多元化、尽可能将关键生产流程外包到近岸地区，并加强需求预测，以减轻关税波动的影响。支付者的参与策略同样必须纳入采购成本上升的影响，重点在于强调减少后续住院和移植需求的卫生经济学论点。总而言之，关税环境凸显了製定策略规划的必要性，以最大限度地减少中断，同时确保患者能够及时获得必要的PFIC治疗。

整合细分情报，揭示治疗类型、药物类别、治疗环境、管道、给药途径、年龄层和PFIC亚型如何影响策略和执行。

在进行局部胆汁淤积症 (PFIC) 的治疗过程中，由于涉及不同的治疗层级、护理环境和患者群体，因此，以细分市场为导向的决策对于客製化开发和商业化至关重要。就治疗类型而言，药物治疗是缓解疾病和症状控制的主要临床策略，其中胆汁酸抑制剂和髂骨胆汁酸转运体抑制剂是重点标靶机制。在药物治疗中，胆汁酸抑制剂（例如考来烯胺和考来维崙）在改善症状和生化指标方面发挥作用，而迴肠胆汁酸转运体抑制剂（例如马拉利西巴和奥德维西巴）旨在减少有害胆汁酸的积累。利福平和熊去氧胆酸等辅助治疗药物在缓解症状和改善生化指标方面也发挥作用。对于难治性或进行性疾病，外科手术（从胆道改道到肝臟移植）则是升级治疗途径。

在药物类别中，区分抗生素、螯合剂、IBAT抑制剂和胆汁酸调变器有助于进一步细化优先排序，因为它们会影响临床试验终点、安全性监测和商业化方案。终端使用者细分突显了不同的需求，例如居家医疗机构、医院住院服务和专科诊所网络，这些都需要客製化的分销、教育和依从性支援。分销管道的选择，包括医院药房、线上药房和零售药房，决定了治疗药物如何到达患者以及如何管理供应保障。给药途径区分了口服和静脉注射产品，并影响依从性策略和临床支持的需求。儿科、青少年和成人年龄层需要适合其年龄的製剂和给药策略，而PFIC亚型（I型、II型和III型）的分类则决定了分子标靶策略、临床试验纳入标准和长期疗效预期。整合这些部分可以更准确地识别患者、设计临床路径，并制定针对 PFIC 治疗复杂现实的上市策略。

美洲、欧洲、中东和非洲以及亚太地区在临床网路、支付方框架和医疗保健基础设施方面的区域差异，决定了医疗服务的可近性和普及性。

PFIC治疗方案的研发、应用和报销深受区域动态的影响，美洲、欧洲、中东和非洲以及亚太地区的临床实践模式和治疗途径有显着差异。在美洲，卓越的医疗中心、完善的移植网络和成熟的专科药房管道支持新型治疗方法的早期应用，但支付方越来越需要可靠的真实世界证据和长期疗效数据来证明高成本治疗方法的合理性。在此背景下，能够证明患者获益显着并建构包含移植项目和儿科肝病中心在内的综合治疗路径的申办方将更具优势。

中东和非洲地区法律规范分散，报销机制各异，因此需要不同的市场进入策略。设有集中式卫生技术评估机构的国家专注于卫生经济模型和疗效比较证据，而其他地区则可能利用管理式准入协议来实现患者早期获得治疗。专科诊所和医院系统在协调护理和提供复杂干预措施方面发挥着至关重要的作用。在亚太全部区域，医疗基础设施的多样性、移植机会的差异以及不同的监管预期，都要求制定灵活的临床和商业计划。一些市场正透过扩大罕见疾病计画来加速推广应用，而有些市场则优先考虑诊断和专科护理能力的建设。总而言之，区域策略必须考虑临床网路成熟度、支付方预期、供应物流和专科药局管道等方面的差异，才能确保PFIC患者获得有效且公平的治疗。

创新者、专业製造商和临床网路如何协调研发、伙伴关係和营运策略，以塑造PFICs领域的竞争地位和招募工作

在PFIC（原发性家族性发炎性疾病）领域，公司层面的动态变化将专业化、策略伙伴关係和适应性商业化策略结合，作为其竞争地位的关键要素。开发标靶药物的创新企业通常与临床中心和学术网路合作，设计能够捕捉重要终点的试验，例如减轻搔痒、改善生化指标或实现无移植生存。专业製药和生物製药开发商透过製剂科学、儿科友善给药途径以及面向监管机构和支付方的数据生成计划来脱颖而出。同时，医疗服务提供者和移植中心作为策略合作伙伴的角色日益凸显，他们支持建立註册登记系统、追踪长期疗效以及推动新型治疗方法的协作式照护路径。

製造商、合约研究与受託製造厂商以及专业经销商之间的合作对于维持特定疗法的持续供应至关重要。能够实现共用生产能力、区域分销中心和整合患者支援服务的策略联盟，可以缩短患者用药时间并降低供应中断的风险。投资于强有力的核准后证据生成（例如自然史研究和真实世界註册研究）的公司，能够向支付方建立更强大的价值提案。最后，将临床差异化与可验证的营运能力（例如病患支援计画和临床医生教育计画）相结合的竞争策略，往往能够加速产品推广，并巩固其在PFIC治疗领域的长期地位。

领导者可以采取实际有效的行动，协调证据产生、供应链韧性和商业策略，以加速PFIC的推广应用并改善患者预后。

产业领导者必须采取一系列协调一致的行动，以确保PFIC的科学进展能够转化为持续的临床和商业性影响。首先，研发项目应优先考虑能够反映患者真实体验和长期器官保存情况的终点指标，并使研究设计与支付方的证据需求保持一致。申办方还应儘早投资于真实世界证据平台和病患登记系统，以连接临床试验数据和长期疗效，并支持医保报销谈判和核准后监测。

同时，与专科药房和居家照护机构建立策略伙伴关係将有助于患者更可靠地获得所需药物。商业策略应针对每个终端使用者进行细緻调整，包括为医院和专科诊所提供教育项目，为居家照护患者提供用药依从性和支持，以及为零售药房和线上药房管道简化获取途径。此外，优先开发适合儿童的配方和给药途径将有助于促进不同年龄层的更广泛应用。最后，加强与移植中心和多学科护理团队的密切合作，有助于确保升级治疗方案切实有效，并将新治疗方法整合到能够改善患者生活品质和长期疗效的综合护理计划中。

结合主要相关人员访谈、临床文献综合和情境分析的严谨混合方法，将检验对PFIC相关人员具有实际意义的见解。

本研究综合分析采用多方法，旨在整合临床专业知识、相关人员的观点以及同侪审查文献中的证据。主要研究包括对临床医生、移植外科医生、专科药剂师和支付方代表进行结构化访谈，以了解治疗选择、供应物流和报销方面的实际考虑。这些质性资讯与近期临床文献的系统性回顾进行交叉比对，以识别PFIC试验中使用的新型治疗机制、相关安全性考量和研究终点。

透过分析医院、专科诊所和居家照护机构的配送实务和护理服务模式，以及考虑影响依从性和患者体验的製剂和给药途径限制因素，我们获得了营运和商业方面的见解。我们透过情境分析评估了供应链的影响，该分析考虑了关税、跨境生产依赖性以及诸如近岸外包和冗余采购等缓解措施的影响。在整个过程中，我们透过与关键意见领袖和临床专案经理的后续咨询来检验所获得的洞见，以确保建议切实可行、符合临床规范，并符合现行法规和支付方的期望。此调查方法优先考虑严谨性、相关人员相关性以及对实际决策的适用性。

一份策略性综合报告，重点阐述了将治疗创新转化为持续改善进行性家族性肝内胆汁淤积症（PFIC）患者预后所需的条件和协作行动。

受科学进步、医疗模式演变和经济限制变化的影响，进行性家族性肝内胆汁淤积症（PFIC）的治疗格局正处于曲折点。靶向调节胆汁酸代谢的药物疗法、完善的多学科诊疗网络以及适应性监管路径，共同为改善进行性胆汁淤积性肝病患者的预后创造了机会。然而，要实现这些益处，需要各方协同努力：一方面，需要提供强有力的证据以说服监管机构和支付方；另一方面，需要製定能够降低外部风险的供应链策略；此外，还需要製定能够反映终端用户需求和当地医疗体系特点的商业化计划。

将临床开发与实际营运准备和以支付方为中心的价值论证相结合的相关人员，将更有能力把治疗潜力转化为可衡量的患者获益。同样重要的是，要与製造商、专科诊所、移植中心和患者权益倡导网络建立伙伴关係，以确保公平且永续的治疗途径。透过这些要素的共同努力，可以推动PFIC患者的早期疗育、降低发病率并改善长期预后。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• odevixibat 的 III 期临床试验数据显示，该药物可显着减轻进行性家族性肝内胆汁淤积症 (PFIC) 患者的搔痒症状并改善胆汁酸谱。
• 针对ABCB11突变的腺结合病毒基因疗法的开发，旨在持续恢復PFIC 2型患者的胆汁分泌
• FXR促效剂研发管线在奥贝胆酸之外取得进展，以增强儿童进行性家族性肝内胆汁淤积症患者的胆汁淤积控制
• 将液态切片生物标记整合到PFIC临床实践中，用于早期检测和疾病进展监测。
• 对新型PFIC疗法进行成本效益分析，重点在于长期医疗资源利用与预算影响
• 一项真实世界证据研究评估了接受髂骨胆汁酸转运抑制剂治疗的PFIC患者的生活品质改善和依从性模式
• 利用数位健康平台建立的协作註册库将规范罕见疾病临床试验的表型分析，并加速病患招募。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗类型分類的进行性遗传性肝内胆汁淤积症治疗市场

• 药物治疗
  • 抗生素
  • 胆汁酸分泌
    • 考来烯胺
    • 科尔塞维鲁姆
  • IVAT抑制剂
    • 马拉利希巴特
    • 奥德维西巴特
  • 利福平
  • 熊去氧胆酸
• 支持性护理
  • 营养支持
  • 症状管理
• 手术介入
  • 胆道改道
  • 肝臟移植

第九章 依药物类别分類的进行性遗传性肝内胆汁淤积症治疗市场

• 抗生素
• 胆汁酸分泌抑制剂
  • 考来烯胺
  • 科尔特维伦
• Ivat抑制剂
  • 马拉利希巴特
  • 奥德维西巴特
• 熊去氧胆酸

第十章 依最终使用者分類的进行性遗传性肝内胆汁淤积症治疗市场

• 居家照护
• 医院
• 专科诊所

第十一章 依通路分類的进行性遗传性肝内胆汁淤积症治疗市场

• 医院药房
• 网路药房
• 零售药房

第十二章 依给药途径分類的进行性遗传性肝内胆汁淤积症治疗市场

• 静脉注射
• 口服

第十三章 依病患年龄组别分類的进行性遗传性肝内胆汁淤积症治疗市场

• 青春期
• 成人
• 孩子们

第十四章 依类型分類的进行性遗传性肝内胆汁淤积症治疗市场

• I型
• II 型
• III型

第十五章 各地区进行性遗传性肝内胆汁淤积症治疗市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十六章 依组别分類的进行性遗传性肝内胆汁淤积症治疗市场

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十七章 各国进行性遗传性肝内胆汁淤积症治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十八章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Albireo Pharma, Inc.
  • Mirum Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie, Inc.
  • Glenmark Pharmaceuticals Limited

The Progressive Familial Intrahepatic Cholestasis Treatment Market is projected to grow by USD 172.81 million at a CAGR of 4.81% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 118.62 million
Estimated Year [2025]	USD 124.40 million
Forecast Year [2032]	USD 172.81 million
CAGR (%)	4.81%

A concise and authoritative overview of the clinical, therapeutic, and operational context for PFIC care that frames strategic priorities across stakeholders

Progressive familial intrahepatic cholestasis (PFIC) represents a set of genetically and clinically heterogeneous cholestatic liver disorders that present complex challenges across diagnosis, clinical management, and long-term care. Patients encounter progressive liver dysfunction from early life onward, often requiring a mix of pharmacologic approaches, supportive interventions, and in many cases surgical procedures. Clinicians, researchers, and health systems are therefore pursuing multimodal strategies that balance immediate symptom control with durable approaches that alter disease biology.

This executive summary frames the contemporary landscape for PFIC treatment by synthesizing developments across therapeutic modalities, regulatory pathways, and care delivery models. It highlights the drivers reshaping clinical priorities, such as new targeted agents designed to reduce intrahepatic bile acid burden, evolving standards for liver transplantation and diversion procedures, and the maturation of specialist care networks. The narrative also emphasizes the importance of aligning clinical innovation with supply chain resilience, payer engagement, and patient-centered care models to ensure that advanced therapies translate into equitable real-world benefit. By setting this context, the introduction prepares the reader for a deeper exploration of transformative shifts, segmentation intelligence, regional considerations, and tactical recommendations aimed at stakeholders across the therapeutic ecosystem.

Emerging therapeutic innovations, adaptive regulatory approaches, and integrated care models converging to redefine treatment paradigms and adoption pathways for PFIC

Over the last several years, a confluence of scientific, regulatory, and care-delivery forces has produced transformative shifts in the PFIC landscape. Advances in molecular genetics and a deeper understanding of bile acid physiology have accelerated the development of targeted pharmacotherapies that directly modulate enterohepatic bile acid circulation. This evolution has expanded options beyond symptom-directed supportive care toward agents that may alter disease trajectory and delay or obviate the need for invasive surgical interventions.

At the same time, clinical practice has begun to embrace more integrated care models that combine specialized hepatology centers, coordinated nutritional support, and earlier referral pathways for transplant evaluation. Regulatory authorities have increasingly offered adaptive pathways and orphan-drug incentives that shorten timelines for therapies addressing ultra-rare diseases, while payers and health systems are refining value frameworks to assess long-term benefits versus upfront costs. The combination of improved diagnostics, a growing pipeline of targeted agents, and evolving reimbursement dialogues has shifted strategic imperatives: sponsors must now plan for differentiated clinical programs, a clear evidence generation strategy for payers, and partnerships with specialty clinics and transplant centers to support adoption and patient monitoring.

Evaluating how United States tariff measures slated for 2025 are poised to affect supply chains, clinical programs, procurement, and patient access for PFIC therapies

Recent tariff actions announced for 2025 within the United States create a new layer of complexity for the PFIC therapeutic ecosystem by affecting the economics and logistics of cross-border supply chains. Many specialized medicines, raw materials, and biologic components rely on international manufacturing and distribution networks. When tariffs increase the landed cost of active pharmaceutical ingredients, finished products, or ancillary devices, sponsors and distributors face pressure to reassess sourcing strategies, inventory practices, and contractual terms with manufacturing partners.

These cost pressures can ripple through procurement practices among hospitals, specialty clinics, and pharmacy channels, compelling tighter negotiations with manufacturers and more stringent evaluation of formulary placements. Clinical development programs are also affected: trial supply budgets, import/export timelines, and site selection may need realignment to maintain continuity of investigational product delivery. In response, stakeholders are prioritizing supply-chain diversification, near-shoring of critical manufacturing steps where feasible, and enhanced demand forecasting to reduce exposure to tariff volatility. Payer engagement strategies must similarly incorporate the implications of higher acquisition costs, focusing on health economic arguments that emphasize downstream reductions in hospitalization or transplantation needs. Overall, the tariff environment underscores the need for strategic planning that minimizes disruption while preserving timely patient access to essential PFIC therapies.

Integrated segmentation intelligence revealing how treatment types, drug classes, care settings, channels, routes, age cohorts, and PFIC subtypes shape strategy and execution

Segment-driven decisioning is essential for tailored development and commercialization in PFIC because the therapeutic journey spans distinct treatment classes, care settings, and patient cohorts. When considering treatment type, pharmacotherapy dominates clinical strategy for disease modification and symptom control, with topical emphasis on bile acid sequestrants and inhibitors of the ileal bile acid transporter as targeted mechanisms. Within pharmacotherapy, bile acid sequestrants such as cholestyramine and colesevelam serve symptomatic and biochemical roles, while IBAT inhibitors-represented by agents like maralixibat and odevixibat-are designed to reduce toxic bile acid accumulation. Complementary options such as rifampicin and ursodeoxycholic acid retain roles in symptom mitigation and biochemical improvement. Supportive care remains foundational, with nutritional support and symptom management critical to maintaining growth and quality of life, while surgical interventions ranging from biliary diversion procedures to liver transplantation provide escalation pathways for refractory or progressive disease.

Drug-class considerations further refine prioritization, with distinctions between antibiotics, sequestrants, IBAT inhibitors, and bile acid modulators influencing clinical trial endpoints, safety monitoring, and commercialization narratives. End-user segmentation highlights the differing needs of homecare environments, hospital inpatient services, and specialty clinic networks, each requiring tailored distribution, education, and adherence support. Distribution-channel choices-including hospital pharmacies, online dispensaries, and retail pharmacies-determine how therapies reach patients and how supply assurance must be managed. Route of administration differentiates products that are oral from those requiring intravenous delivery, shaping adherence strategies and clinical support requirements. Age-group segmentation across children, adolescents, and adults mandates age-appropriate formulations and dosing strategies, while PFIC subtype distinctions among Type I, Type II, and Type III drive molecularly targeted approaches, trial inclusion criteria, and long-term outcome expectations. Synthesizing these segments enables more precise patient identification, clinical pathway design, and go-to-market strategies tailored to the complex realities of PFIC care.

Regional differences in clinical networks, payer frameworks, and healthcare infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access and adoption dynamics

Regional dynamics significantly influence how PFIC therapies are developed, adopted, and reimbursed, with important distinctions across the Americas, Europe Middle East & Africa, and Asia-Pacific that affect clinical practice patterns and access pathways. In the Americas, concentrated centers of excellence, established transplantation networks, and mature specialty pharmacy channels support early adoption of novel therapies, yet payers increasingly demand robust real-world evidence and longitudinal outcomes to justify coverage for high-cost interventions. This environment favors sponsors that can demonstrate clear patient-level benefits and create integrated care pathways involving transplant programs and pediatric hepatology centers.

In Europe Middle East & Africa, fragmented regulatory frameworks and variable reimbursement landscapes require differentiated market access approaches. Nations with centralized health technology assessment bodies emphasize health-economic modeling and comparative-effectiveness evidence, while other jurisdictions may leverage managed access agreements to enable early patient access. Specialty clinics and hospital systems play a vital role in coordinating care and delivering complex interventions. Across the Asia-Pacific region, heterogeneity in healthcare infrastructure, variable access to transplantation, and differing regulatory expectations necessitate flexible clinical and commercial plans. Some markets are accelerating adoption through expanded orphan-disease programs, while others prioritize capacity-building for diagnosis and specialist care. Taken together, regional strategies must account for differences in clinical networks, payer expectations, supply logistics, and the relative maturity of specialty pharmacy channels to achieve effective and equitable access for PFIC patients.

How innovators, specialty manufacturers, and clinical networks are aligning R&D, partnerships, and operational strategies to shape competitive positioning and adoption in PFIC

Company-level dynamics in PFIC combine specialization, strategic partnerships, and adaptive commercialization strategies as essential elements of competitive positioning. Innovators developing targeted agents often partner with clinical centers and academic networks to design trials that capture meaningful endpoints such as pruritus reduction, biochemical improvement, and transplantation-free survival. Specialty pharmaceutical firms and biologic developers differentiate through formulation science, pediatric-friendly administration routes, and data generation plans that address both regulators and payers. Meanwhile, providers and transplant centers increasingly act as strategic partners, supporting registry development, long-term outcome tracking, and coordinated care pathways that facilitate adoption of novel therapies.

Collaborations between manufacturers, contract development and manufacturing organizations, and specialty distributors are also central to maintaining supply continuity for niche therapeutic products. Strategic alliances that enable shared manufacturing capacity, regional distribution hubs, and integrated patient support services reduce time-to-patient and mitigate risks from supply disruptions. Companies that invest in robust post-approval evidence generation-including natural history studies and real-world registries-build stronger value propositions for payers. Finally, competitive strategies that combine clinical differentiation with demonstrable operational readiness, such as patient support programs and clinician education initiatives, tend to accelerate uptake and reinforce long-term position in the PFIC therapeutic space.

Practical, high-impact actions for leaders to align evidence generation, supply resilience, and commercial strategies to accelerate adoption and improve patient outcomes in PFIC

Industry leaders must adopt a coordinated set of actions to ensure that scientific advances in PFIC translate into sustained clinical and commercial impact. First, development programs should prioritize endpoints that reflect meaningful patient experiences and long-term organ preservation, aligning trial designs with payer evidence needs. Sponsors should also invest early in real-world evidence platforms and patient registries that can bridge clinical trial data to long-term outcomes, supporting reimbursement negotiations and post-authorization monitoring.

Operationally, diversifying manufacturing and distribution arrangements will reduce exposure to tariff-induced price pressures and logistical delays, while strategic partnerships with specialty pharmacies and homecare providers will enable more reliable patient access. Commercial strategies must be nuanced for different end users, with tailored educational programs for hospitals and specialty clinics, adherence and support offerings for homecare patients, and streamlined access pathways for retail and online pharmacy channels. Additionally, prioritizing pediatric-friendly formulations and administration routes will support broader adoption across age cohorts. Lastly, fostering closer collaboration with transplant centers and multidisciplinary care teams will ensure that escalation pathways remain fit-for-purpose and that new therapies are integrated into comprehensive care plans that improve patient quality of life and long-term outcomes.

A rigorous mixed-methods approach combining primary stakeholder interviews, clinical literature synthesis, and scenario analysis to validate actionable insights for PFIC stakeholders

This research synthesis is grounded in a multi-method approach designed to integrate clinical expertise, stakeholder perspectives, and evidence from peer-reviewed literature. Primary research included structured interviews with clinicians, transplant surgeons, specialty pharmacists, and payer representatives to capture practical considerations around treatment selection, supply logistics, and reimbursement. These qualitative inputs were triangulated with systematic review of recent clinical literature to identify emerging therapeutic mechanisms, relevant safety considerations, and trial endpoints used in PFIC studies.

Operational and commercial insights were informed by analysis of distribution practices and care-delivery models across hospital, specialty clinic, and homecare settings, along with examination of formulation and route-of-administration constraints that affect adherence and patient experience. Supply-chain implications were assessed through scenario analysis that considered tariff impacts, cross-border manufacturing dependencies, and mitigation strategies such as near-shoring and redundant sourcing. Throughout the process, findings were validated through follow-up consultations with key opinion leaders and clinical program managers to ensure that recommendations are practical, clinically relevant, and aligned with current regulatory and payer expectations. This methodology prioritizes rigor, stakeholder relevance, and applicability to real-world decision-making.

A strategic synthesis highlighting the conditions and collaborative actions required to convert therapeutic innovation into sustainable improvements in PFIC patient outcomes

The PFIC treatment landscape is at an inflection point driven by scientific advances, evolving care models, and shifting economic constraints. Targeted pharmacotherapies that modulate bile acid handling, improvements in clinical networks for multidisciplinary care, and adaptive regulatory pathways collectively create an opportunity to improve outcomes for patients facing progressive cholestatic liver disease. Yet realizing these benefits requires coordinated action: robust evidence generation that speaks to regulators and payers, supply-chain strategies that mitigate external risks, and targeted commercialization plans that reflect the nuances of end-user needs and regional healthcare systems.

Stakeholders who align clinical development with pragmatic operational readiness and payer-centered value demonstration will be best positioned to translate therapeutic potential into measurable patient benefit. Equally important is the cultivation of partnerships across manufacturers, specialty clinics, transplant centers, and patient advocacy networks to ensure that access pathways are equitable and sustainable. If these elements are addressed in concert, the community can move toward earlier intervention, reduced morbidity, and improved long-term outcomes for individuals living with PFIC.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Phase iii trial data on odevixibat demonstrating significant pruritus reduction and improved bile acid profiles in PFIC patients
• 5.2. Development of adeno-associated virus gene therapies targeting ABCB11 mutations for durable restoration of bile secretion in PFIC type 2
• 5.3. Advancements in FXR agonists pipeline beyond obeticholic acid for enhanced cholestasis control in pediatric PFIC cohorts
• 5.4. Integration of liquid biopsy biomarkers for early detection and monitoring of disease progression in PFIC clinical practice
• 5.5. Cost-effectiveness analyses of emerging PFIC treatments highlighting long-term healthcare resource utilization and budget impact
• 5.6. Real-world evidence studies assessing quality-of-life improvements and adherence patterns in PFIC patients treated with ileal bile acid transport inhibitors
• 5.7. Collaborative registries leveraging digital health platforms to standardize PFIC phenotyping and accelerate patient recruitment for rare disease trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Treatment Type

• 8.1. Pharmacotherapy
  • 8.1.1. Antibiotics
  • 8.1.2. Bile Acid Sequestrants
    • 8.1.2.1. Cholestyramine
    • 8.1.2.2. Colesevelam
  • 8.1.3. Ibat Inhibitors
    • 8.1.3.1. Maralixibat
    • 8.1.3.2. Odevixibat
  • 8.1.4. Rifampicin
  • 8.1.5. Ursodeoxycholic Acid
• 8.2. Supportive Care
  • 8.2.1. Nutritional Support
  • 8.2.2. Symptom Management
• 8.3. Surgical Interventions
  • 8.3.1. Biliary Diversion
  • 8.3.2. Liver Transplantation

9. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Class

• 9.1. Antibiotics
• 9.2. Bile Acid Sequestrants
  • 9.2.1. Cholestyramine
  • 9.2.2. Colesevelam
• 9.3. Ibat Inhibitors
  • 9.3.1. Maralixibat
  • 9.3.2. Odevixibat
• 9.4. Ursodeoxycholic Acid

10. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End User

• 10.1. Homecare
• 10.2. Hospitals
• 10.3. Specialty Clinics

11. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

• 11.1. Hospital Pharmacy
• 11.2. Online Pharmacy
• 11.3. Retail Pharmacy

12. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Route Of Administration

• 12.1. Intravenous
• 12.2. Oral

13. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Patient Age Group

• 13.1. Adolescents
• 13.2. Adults
• 13.3. Children

14. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Pfic Type

• 14.1. Type I
• 14.2. Type II
• 14.3. Type III

15. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Share Analysis, 2024
• 18.2. FPNV Positioning Matrix, 2024
• 18.3. Competitive Analysis
  • 18.3.1. Albireo Pharma, Inc.
  • 18.3.2. Mirum Pharmaceuticals, Inc.
  • 18.3.3. Teva Pharmaceutical Industries Ltd.
  • 18.3.4. AbbVie, Inc.
  • 18.3.5. Glenmark Pharmaceuticals Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 34. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILIARY DIVERSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY MARALIXIBAT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ODEVIXIBAT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION